期刊
ATHEROSCLEROSIS SUPPLEMENTS
卷 13, 期 1, 页码 1-10出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosissup.2012.06.001
关键词
Statins; New-onset diabetes; Risk; Diabetogenic; Evidence
资金
- Pfizer
- Kowa
Multiple clinical trials have demonstrated the beneficial effects of statins in lowering levels of low-density lipoprotein and in the prevention of cardiovascular disease. However, although statins have a good safety profile, a debate has been ongoing as to whether use of statins increases risk of new-onset diabetes. Recent large scale meta-analyses of statin trials support the concept of a diabetogenic effect of statins, as do some other small trials assessing changes in glycaemia parameters and insulin levels. However, a definitive mechanism of action has not yet been elucidated. Nevertheless, the level of evidence has been sufficient to lead the FDA to make a change to the labelling of statins. This review assesses the current available evidence and offers a clinical perspective. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据